> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA OKs Expanded Use of Furoscix
- URL: https://www.fdaweb.com/fda-oks-expanded-use-of-furoscix/
- Published: 2025-03-06T12:00:00.000Z
- Updated: 2026-09-14T14:54:42.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5158781

FDA has approved a scPharmaceuticals supplemental NDA for Furoscix (furosemide injection) to expand the indication to include treatment of edema in patients with chronic kidney disease. Previously, Furoscix was approved for treating edema (i.e., congestion, fluid overload, or hypervolemia) in adult patients with chronic heart failure.

The company says the drug is contraindicated in patients with anuria and in patients with a history of hypersensitivity to furosemide, any component of the Furoscix formulation, or medical adhesives. “Furosemide may cause fluid, electrolyte, and metabolic abnormalities, particularly in patients receiving higher doses, patients with inadequate oral electrolyte intake, and in elderly patients,” it says. Serum electrolytes, creatinine, glucose, and uric acid should be monitored frequently during furosemide therapy, it adds.